This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamaguchi, T.
Right arrow Articles by Kohno, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamaguchi, T.
Right arrow Articles by Kohno, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2000, p. 1381-1382, Vol. 44, No. 5
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

In Vitro Activity of Telithromycin (HMR3647), a New Ketolide, against Clinical Isolates of Mycoplasma pneumoniae in Japan

Toshiyuki Yamaguchi,1,* Yoichi Hirakata,1 Koichi Izumikawa,1 Yoshitsugu Miyazaki,1 Shigefumi Maesaki,2 Kazunori Tomono,2 Yasuaki Yamada,1 Shimeru Kamihira,1 and Shigeru Kohno2

Department of Laboratory Medicine1 and the Second Department of Internal Medicine,2 Nagasaki University School of Medicine, Nagasaki 852-8501, Japan

Received 20 September 1999/Returned for modification 13 January 2000/Accepted 15 February 2000

The in vitro activity of telithromycin (HMR3647), a new ketolide, against Mycoplasma pneumoniae was determined by the broth microdilution test using 41 clinical isolates obtained in Japan, as compared with those of five macrolides (erythromycin, clarithromycin, roxithromycin, azithromycin, and josamycin), minocycline, and levofloxacin. Telithromycin was less potent than azithromycin, but it was more active than four other macrolides, minocycline, and levofloxacin; its MICs at which 50 and 90% of the isolates tested were inhibited were both 0.00097 µg/ml, justifying clinical studies to determine its efficacy for treatment of M. pneumoniae.


* Corresponding author. Mailing address: Department of Laboratory Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. Phone: 81 (95)-849-7420. Fax: 81 (95)-849-7422. E-mail: toshi-ngs{at}umin.ac.jp.


Antimicrobial Agents and Chemotherapy, May 2000, p. 1381-1382, Vol. 44, No. 5
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Johnston, S. L., Blasi, F., Black, P. N., Martin, R. J., Farrell, D. J., Nieman, R. B., the TELICAST Investigators, (2006). The Effect of Telithromycin in Acute Exacerbations of Asthma. NEJM 354: 1589-1600 [Abstract] [Full Text]  
  • Waites, K. B., Crabb, D. M., Duffy, L. B. (2003). In Vitro Activities of ABT-773 and Other Antimicrobials against Human Mycoplasmas. Antimicrob. Agents Chemother. 47: 39-42 [Abstract] [Full Text]  
  • Maurin, M., Bryskier, A., Raoult, D. (2002). Antibiotic Susceptibilities of Parachlamydia acanthamoeba in Amoebae. Antimicrob. Agents Chemother. 46: 3065-3067 [Abstract] [Full Text]  
  • Kenny, G. E., Cartwright, F. D. (2001). Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, Dalfopristin, Dirithromycin, Evernimicin, Gatifloxacin, Linezolid, Moxifloxacin, Quinupristin-Dalfopristin, and Telithromycin Compared to Their Susceptibilities to Reference Macrolides, Tetracyclines, and Quinolones. Antimicrob. Agents Chemother. 45: 2604-2608 [Abstract] [Full Text]  
  • Pereyre, S., de Barbeyrac, B., Renaudin, H., Poutiers, F., Bebear, C., Bebear, C. M. (2001). In vitro activity of midecamycin diacetate against Mycoplasma pneumoniae and Chlamydia pneumoniae. J Antimicrob Chemother 47: 240-241 [Full Text]